Mobile Health Intervention to Improve Exercise in Pediatric PH

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age10-21
SponsorVanderbilt University Medical Center

About this trial

Children and adults with pulmonary arterial hypertension (PAH) have severely reduced daily activity compared to healthy populations. In adults, investigators recently demonstrated that lower baseline daily step counts associated with increased risk of hospitalization and worsening WHO functional class; similarly, reduced step counts associate with hospitalization in children with PAH. This application builds on our recently completed NIH-funded pilot mobile health (mHealth) trial in adult patients with PAH which demonstrated the ability to remotely increase step counts. The investigators now aim to: (1) adapt our mHealth intervention to the developmental needs and interests of adolescents; and, (2) determine if our intervention increases step counts in adolescents, providing the foundation for a larger trial to assess the impact on quality of life and clinical outcomes.

Eligibility criteria

Qualifiers

Adolescents between ages 10-21 years.

Diagnosed with WHO Group 1 PAH or WHO Group 4 PH (CTEPH)

WHO functional class I-III

Stable PAH-specific medication regimen for three months prior to enrollment. Subjects with only a single diuretic adjustment in the prior three months will be included. Adjustments in IV prostacyclin for side effect management are allowed.

Disqualifiers

Prohibited from normal activity due to wheelchair bound status, bed bound status, reliance on a cane/walker, activity-limiting angina, activity-limiting osteoarthritis, or other condition that limits activity.

Pregnancy

Diagnosis of PAH etiology other than idiopathic, heritable, or associated.

Functional class IV heart failure

Trial design

Treatments tested in this trial

  • mHealth Intervention
  • Usual Care

Treatment groups

50 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Vanderbilt University Medical Center

Lead sponsor

University of California, San Francisco

Collaborator

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator